



City Research Online

City St George's, University of London

Citation: Sanders, J., Makariou, N., Toccock, A., Magboo, R., Thomas, A. & Aitken, L. M. (2022). Preoperative risk assessment tools for morbidity after cardiac surgery: a systematic review. *European Journal of Cardiovascular Nursing*, 21(7), pp. 655-664. doi: 10.1093/eurjcn/zvac003

This is the accepted version of the paper.

This version of the publication may differ from the final published version. To cite this item please consult the publisher's version.

Permanent repository link: <https://openaccess.city.ac.uk/id/eprint/27842/>

Link to published version: <https://doi.org/10.1093/eurjcn/zvac003>

Copyright and Reuse: Copyright and Moral Rights remain with the author(s) and/or copyright holders. Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge, unless otherwise indicated, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. For full details of reuse please refer to [City Research Online policy](#).

**PRE-OPERATIVE RISK ASSESSMENT TOOLS FOR MORBIDITY AFTER CARDIAC SURGERY: A
SYSTEMATIC REVIEW**

Julie Sanders^a; Nicole Makariou^b; Adam Tocock^c; Rosalie Magboo^d; Ashley Thomas^e; Leanne M Aitken^f.

^aProfessor Julie Sanders: St Bartholomew's Hospital, West Smithfield, Barts Health NHS Trust. London. UK and Clinical Professor Cardiovascular Nursing, William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London. UK. Email: j.sanders@qmul.ac.uk

^bMs Nicole Makariou: Barts and the London Medical School, Charterhouse Square, Queen Mary University of London, London. UK. Email: n.makariou@smd16.qmul.ac.uk

^cMr Adam Tocock: Knowledge and Library Services, St Bartholomew's Hospital, West Smithfield, Barts Health NHS Trust, London. UK. Email: adam.tocock@nhs.net

^dMrs Rosalie Magboo: Critical Care, St Bartholomew's Hospital, West Smithfield, Barts Health NHS Trust, London. UK and The William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London. UK. Email: rosalie.renamagboo@nhs.net

^eMr Ashley Thomas: Critical Care, St Bartholomew's Hospital, West Smithfield, Barts Health NHS Trust, London. UK and The William Harvey Research Institute, Charterhouse Square, Queen Mary University of London, London. UK. Email: ashleythomas@nhs.net

^fProfessor Leanne M Aitken: School of Health Sciences, Northampton Square, City, University of London, London. UK. Email: leanne.aitken.1@city.ac.uk

CORRESPONDING AUTHOR: Professor Julie Sanders, Director of Clinical Research, St Bartholomew's Hospital, West Smithfield, Barts Health NHS Trust. West Smithfield. London. EC1A 7DN. Telephone: +44 (0)7960 311979. Email address: j.sanders@qmul.ac.uk. Twitter: [@julesanders2](https://twitter.com/julesanders2)

**PRE-OPERATIVE RISK ASSESSMENT TOOLS FOR MORBIDITY AFTER CARDIAC SURGERY: A
SYSTEMATIC REVIEW**

ABSTRACT

BACKGROUND

Post-operative morbidity places considerable burden on health and resources. Thus, strategies to identify, predict and reduce post-operative morbidity are needed.

AIMS

To identify and explore existing pre-operative risk assessment tools for morbidity after cardiac surgery.

METHODS

Electronic databases (including MEDLINE, CINAHL, Embase) were searched to December 2020 for pre-operative risk assessment models for morbidity after adult cardiac surgery. Models exploring one isolated post-operative morbidity and those in patients having heart transplantation or congenital surgery were excluded. Data extraction and quality assessments were undertaken by two authors.

RESULTS

From 2,251 identified papers, 22 models were found. The majority (54.5%) were developed in USA or Canada, defined morbidity outcome within the in-hospital period (90.9%), and focused on major morbidity. Considerable variation in morbidity definition was identified, with morbidity incidence between 4.3% and 52%. The majority (45.5%) defined morbidity and mortality separately but combined them to develop one model, while seven studies (33.3%) constructed a morbidity-specific model. Models contained between five to 50 variables. Commonly included variables were age,

emergency surgery, left ventricular dysfunction and reoperation/previous cardiac surgery, although definition differences across studies were observed. All models demonstrated at least reasonable discriminatory power (area under receiver operating curve (0.61-0.82)).

CONCLUSION

Despite the methodological heterogeneity across models, all demonstrated at least reasonable discriminatory power and could be implemented depending on local preferences. Future strategies to identify, predict and reduce morbidity after cardiac surgery should consider the aging population and those with minor and/or multiple complex morbidities.

KEYWORDS: post-operative morbidity; cardiac surgery; pre-operative risk; risk prediction models; morbidity outcome

PRE-OPERATIVE RISK ASSESSMENT TOOLS FOR MORBIDITY AFTER CARDIAC SURGERY: A SYSTEMATIC REVIEW

INTRODUCTION

It is widely recognised that mortality alone provides only a crude representation of surgical quality and that high quality surgical care should include mortality, morbidity and patient-reported outcomes¹. In particular, post-operative complications are a serious global concern affecting up to 16.8% of patients². In cardiac surgery, where over one million cardiac surgeries are performed worldwide each year³, up to 48% of patients experience at least one complication⁴. Those experiencing post-operative complications experience increased intensive care length of stay (LOS)⁴, hospital LOS^{4, 5, 6}, substantial morbidity at 6-weeks after surgery (between 28%⁷ and 38.9%⁸, and readmission requirement (between 6%⁷ and 15.3%⁸). Moreover, almost a quarter of cardiac surgery patients require community health service support in the initial period after discharge⁷ and those who suffer post-operative complications also experience worse quality of life⁹ lasting up to three years after surgery¹⁰ and report increased anxiety and fear of dying¹¹.

In addition to the patient and societal health burden, this poses a huge financial and organisational load on health care systems. Data from the Society of Thoracic Surgeons (STS) suggests the total cost of complications after isolated coronary artery bypass graft surgery (CABG) over the last 10 years was \$78.6million in the USA alone¹². More specifically, the average in-hospital incremental cost of experiencing any complication after CABG is approximately \$15,000 per patient¹³, higher in those undergoing combined CABG and valve surgery⁵, with additional morbidities exponentially increasing costs¹². Such costs, and the associated challenges imposed on healthcare delivery services, will only continue to increase as surgical complexity, increasing patient age and associated co-morbid conditions also increase¹².

Despite this increasing burden, few countries reliably record post-operative morbidity outcomes after cardiac surgery¹⁴ due to its considered subjective and imprecise nature¹⁵. That said, greater emphasis has been placed on morbidity outcome in recent years with both the STS National Database (USA) and the National Institute of Cardiovascular Outcomes Research Adult Cardiac Surgery (UK) reporting some morbidity outcomes at national level (for example, reoperation for bleeding or wound infection, post-operative stroke or post-operative renal failure). However, there lacks an international consensus or standardised definition for post-operative morbidity and clinical endpoints in cardiac surgery trials are measured and reported inconsistently^{16, 17}. This poses considerable challenges as there is a specific need to be able to identify, measure and then accurately predict complications after cardiac surgery¹². If strategies to identify, predict and then subsequently reduce post-operative morbidity after cardiac surgery can be found this will improve patient well-being, reduce healthcare costs and increase healthcare service efficiency.

Thus, we sought to undertake a systematic review of pre-operative risk assessment tools of post-operative morbidity after cardiac surgery to identify and examine the existing tools used to define, measure and assess pre-operative risk of post-operative morbidity after cardiac surgery.

METHODS

This review was registered on PROSPERO, an international prospective register of systematic review (February 2019, reference CRD42019120080).

Protocol and registration

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines¹⁸.

Eligibility criteria

All studies that develop (with or without validation) a pre-operative risk assessment tool of post-operative morbidity after cardiac surgery were eligible for inclusion. Studies were included if they met the following inclusion and exclusion criteria: *Population*: adults (≥ 18 years of age) undergoing any form of cardiac surgery (including coronary artery bypass grafts and/or valve surgery in isolation or combination) but excluding those undergoing heart transplant, cardiology procedures (for example, percutaneous coronary intervention or Transcatheter Aortic Valve Implantation); *Outcome*: morbidity after cardiac surgery, excluding those that assess one isolated post-operative morbidity outcome (for example, stroke or bleeding only). Studies were not excluded on the basis of publication date or quality assessment outcome, but were required to be available in English language.

Information sources

A search of MEDLINE, Cumulated Index of Nursing and Allied Health Literature, Embase, British Nursing Index, the Cochrane Library and ClinicalTrials.gov (www.clinicaltrials.gov) was undertaken for relevant papers published up to and including December 2020 (last search date 14th December 2020). Identified systematic reviews were reviewed to identify any additional tools.

Search strategy

The above data sources were searched using a strategy comprised of title/abstract text terms paired with (major) exploded Medical Subject Heading (MeSH) terms, or equivalent, in the following combinations, as per the Cochrane Library search: (*MeSH descriptor*: [Thoracic Surgery] *explode all trees* OR *MeSH descriptor*: [Cardiovascular Surgical Procedures] *explode all trees* OR (((cardiac OR heart*) NEXT (surge* OR surgical*)) OR CABG OR "coronary artery bypass"):ti,ab,kw) AND (*MeSH descriptor*: [Morbidity] *explode all trees* OR (Morbidity*):ti,ab,kw) AND (*MeSH descriptor*: [Risk Assessment] *explode all trees* OR (risk* NEXT (assess* OR scor* OR tool*)):ti,ab,kw). Clinicaltrials.gov

(www.clinicaltrials.gov) was also searched for trials-in-progress, and citation searches were performed on relevant papers.

Study selection

Two rounds of screening occurred. First, a title and abstract review was undertaken followed by a full paper review of those included from the first screening. All screening was undertaken independently by two authors, in accordance with the inclusion and exclusion criteria, with a third author reviewing any discrepancies between authors. The full-text paper of potential studies identified through systematic reviews were obtained and were also screened as per the above process.

Data collection and syntheses (data items and data collection process)

Data extraction included primary author, date of publication, country of study, study design, type of surgery, sample size (in development and validation datasets, where appropriate), definition of morbidity use, morbidity rate, variables (and attributed scores) included in the final tool, and reliability and validity assessment outcome. All data were extracted and collated into a standardised proforma by two authors, with differences resolved through discussion until consensus achieved.

Risk of bias and quality assessment

All included papers were reviewed for quality by two authors using the Critical Appraisal Skills Programme template for clinical prediction rule¹⁹. A risk of bias graph was generated²⁰ and studies were not excluded on the basis of the quality assessment.

Analysis

Meta-analysis was not possible due to the heterogeneity of studies. Thus, results were summarised using descriptive statistics, tables and narrative synthesis, as appropriate. Interpretation of the

discriminatory power of the models followed that described by Hosmer and Lemeshow²¹. MedCalc® version 19.7.4 was used to generate a forest plot to compare the discriminatory power of each the models. Interpretation of the analysis was discussed and agreed by all members of the authorship team.

RESULTS

Study selection

A total of 2251 non-duplicate papers were identified for possible inclusion (Figure 1) with 105 papers undergoing independent full-text assessment. This resulted in 22 papers being included for data analysis that described the development of a pre-operative risk assessment tool for post-operative morbidity after cardiac surgery. A complete reference list of all included studies is presented in Supplementary Table 1.

Study characteristics

The study characteristics of the 22 included studies are detailed in Tables 1 and 2. The majority of studies were conducted in USA or Canada (n=12 (54.5%)) (Table 1), with just over a quarter (n=6 (27.3%)) published in the last 10 years. Equal proportions of tools were developed in mixed cohorts of cardiac surgery patients and those specifically undergoing CABG (n=9 (40.9%)), four (18.2%) were developed specifically in valve surgery patients^{22, 23, 24, 25} and two focused on risk assessment in the elderly (>70 years²⁶; >80 years²⁷). More recently, focus has been on adapting existing models, for example, combining tools²⁶, and adding biomarkers^{28, 29} and echo parameters²³. Overall, development set sample sizes ranged from 152²⁶ to 670,830²⁵, while almost all defined outcome within the in-hospital post-operative period (n=20 (90.9%)). Only one study included morbidity outcome up to six months after surgery³⁰.

Risk of bias

Figure 2 demonstrates the risk of bias across studies. While the vast majority conducted the development of the models in an appropriate cohort of patients, just under half did not validate the model in a different group of patients. Furthermore, in almost three-quarters of studies performance or detection bias was detected or unclear, although the clinical prediction rule was clearly defined in over 75% of studies. Considering studies individually (Figure 3), only three studies demonstrated no bias in any category^{31,32, 25}, one study demonstrated bias in all categories and another was unclear in all but the sample population bias category³³.

Definition of post-operative morbidity

Across studies four broad types of definition of morbidity were used (Table 2). Two studies defined morbidity using a surrogate marker (LOS >12 days³⁴, LOS >10 days²², while the majority (n=10), and all studies pre-1996, defined morbidity and mortality separately but combined them to develop one model. Similarly, three further studies included death within the morbidity definition^{31, 32, 35}. The construction of separate models for mortality and morbidity was first reported in 2000³⁶ with seven of 12 studies (58.3%) from this time defining and constructing a separate model for post-operative morbidity. However, within these models only two studies used the same definition of morbidity (Hsieh et al 2007²⁷ used that of Dupuis et al 2001³⁷) (Supplementary Table 1), highlighting the variation of morbidity definitions. The majority defined morbidity as severe morbidity, including a range of variables of varying definitions/criteria, while only Magovern and colleagues defined morbidity as either a major or minor complication³¹.

Incidence of post-operative operative morbidity

Overall, the majority of studies (n=9, 40.9%) reported post-operative morbidity incidence between 20% to 30%, although the range across studies was 4.3%³⁵ to 52%^{31, 27}. However, it is important to note that Hsieh et al only included those >80 years old²⁷, and is considerably higher than that

reported by Dupuis et al using the same morbidity definition but in a younger cohort³⁷. Equally, as highlighted previously, Magovern et al was the only study to include both major and minor complications (36% minor complication, 16% major complication)³¹. The reverse is true for Fortescue et al where only five serious adverse events were included in the morbidity definition (death, renal failure, myocardial infarction, cardiac arrest, stroke and coma)³⁵, which are uncommonly experienced after cardiac surgery³⁸.

Pre-operative risk assessment model

Six models either used statements or categories to assess risk^{37,22} or, as detailed previously, combined or modified existing scores^{26,28,29,23}. Of the newly developed models, including those using EuroSCORE, the number of variables included in a model ranged from six³² to 50²⁵. Overall, 94 variables were included across studies with the highly common variables identified as age (n=16), emergency surgery (n=14), left ventricular dysfunction/ejection function (n=14), reoperation/previous cardiac surgery (n=13), renal dysfunction/failure (including creatinine level categories) (n=11) and gender (n=10), where female gender was consistently identified as higher risk (n=8) (Supplementary Table 1). However, despite some variables being commonly included in the models, considerable variations in the definitions of the variables existed. For example, where categorised, eight different age, seven different left ventricular dysfunction/ejection function and eight different renal function definitions were identified. Considering those models defining and measuring post-operative morbidity only (n=7) the common variables were similar and included age (n=7), left ventricular dysfunction/ejection function (n=6), renal dysfunction/failure (including creatinine level categories) (n=4), combined surgery (n=4), lung disease (n=4) and gender (n=4). The discriminatory power of each model is shown in Figure 4, excluding three early models that did not report the area under the receiver operating characteristic curve (area under ROC) or C-statistic^{39, 40, 41}. Four studies demonstrated poor discriminatory power (0.6-0.7) while fair (0.7-0.8) or good

(0.8-0.9) discriminatory power was demonstrated in two-thirds of the models (fair n=12 (54.5%); good n=3 (13.6%). No models demonstrated excellent discriminatory power (0.9-1.0).

DISCUSSION

The impact of post-operative morbidity after cardiac surgery, on in-hospital⁴, post-discharge⁸ physical health and quality of life⁹, and the associated financial burden¹², means that strategies to identify, predict and reduce morbidity after cardiac surgery are needed. Our systematic review identified 22 models of pre-operative risk assessment of morbidity after cardiac surgery. There are several findings of note from these studies. Firstly, there is a recognition of a shift over time in how post-operative morbidity has been defined and measured as the relevance, impact and importance of post-operative morbidity has heightened. Secondly, there remains ongoing challenges relating to varying morbidity definitions resulting in a multitude of prediction models using different outcomes;. Thirdly, there is still an overwhelming focus on in-hospital morbidity outcome despite the evidence supporting impact beyond discharge and potentially for several years and finally, only three models demonstrated 'good' discriminatory power while only one of the 22 models considered both major and minor complications. However, it is also interesting to note that morbidity outcome for those undergoing valve surgery is beginning to be considered separately from CABG with four models now available focusing on this patient group.

Increasing age and risk profile

Cardiac surgery is experiencing an increasing age and risk profile of patients although mortality has continued to fall⁴². Despite this, considerable post-operative morbidity was reported in those over 70 years old (24.3%)²⁶ and 80 years old (51.6%)²⁷. Clearly, the differences in definition influence interpretation of these figures but there are two noteworthy points. Firstly, Hsieh and colleagues used the same morbidity definition as the Cardiac Anaesthesia Risk Evaluation Score model³⁷, which included all cardiac surgery patients and identified a morbidity rate of 20.7% in the development and

22.2% in the validation dataset. Secondly, Afilalo and colleagues added frailty and disability scales to known mortality prediction tools and reported improved model discrimination (compared to mortality prediction alone) for post-operative morbidity²⁶. This suggests that elderly patients experience greater post-operative morbidity and that consideration of pre-operative frailty and disability may be useful in predicting post-operative morbidity risk. As it is expected that any life expectancy gains over the next 20 years will be spent living with multiple complex morbidities, efforts on prevention and efficient service provision is needed⁴³.

Utility in practice

A fundamental challenge of clinical risk prediction scores is their utility in practice⁴⁴. Since operative mortality has been found to be associated with both the number and severity of complications after cardiac surgery⁴⁵, and operative mortality risk tools are routinely used in practice, it is not unreasonable to consider whether existing mortality risk prediction tools may also have value in morbidity prediction. Certainly, EuroSCORE, developed to predict operative mortality risk and used widely across Europe, has been applied to explore post-operative morbidity risk prediction. Indeed, two tools identified in this review^{28,29} added biomarkers to the EuroSCORE to create new models. Unsurprisingly, due to its discriminatory power in predicting operative mortality, EuroSCORE appears to perform reasonably well in predicting overall in-hospital major morbidity incidence^{36,46}. However, EuroSCORE only predicts some, but not all, major (for example, stroke, acute renal failure, respiratory infection, bleeding, myocardial infarction) post-operative complications^{47, 46, 48, 49} and these results are also inconsistent across studies. Equally, previous work has highlighted that different risk factors are associated with morbidity outcome as time from surgery progresses. Thus, accepted risk factors and models for operative mortality may only be useful for predicting morbidity risk in the first few critical days of recovery⁵⁰. This principle may also be applied to the vast majority of models in this review, since almost all only considered in-hospital morbidity and major morbidities.

The 'holy grail' of prognostic factor research is to improve patient outcomes by providing a personalised approach to healthcare and risk prediction⁵¹ and how these factors can be used to improve patient or treatment outcomes⁵². Clinical risk prediction scores are an important driver for person-centred care⁴⁴, at a time when shared decision-making to meaningfully improve outcomes that are important to patients⁵³ is advocated. Specifically, in the UK these currently include improving the outcomes of frail heart surgery patients and those with chronic conditions, including long-term outcomes⁵⁴. Enhanced Recovery After Surgery cardiac programmes recognise the culture-shift to a person-centred system of care and the importance of the multidisciplinary team in this to optimise patient outcomes and experience⁵⁵. Certainly, nurses and allied professionals working in primary care, optimisation or pre-operative clinics are ideally placed to use clinical risk prediction scores to provide this level of personalised care prior to surgery⁵⁶.

Although few countries to date have reliably recorded post-operative morbidity after cardiac surgery¹⁴, efforts to do so are being progressed^{57,42}. This provides the opportunity for more detailed and accurate identification, prediction and subsequent reduction of post-operative morbidity in the future.

Study limitations

This review has three main limitations. Firstly, no studies were excluded on the basis of the quality assessment. This was to enable full exploration of all the models available, although as the results detail, the studies were of varying quality. Secondly, we purposefully only included pre-operative risk assessment tools, excluding those that included intra-operative (and post-operative) variables. If strategies to predict, and then subsequently reduce, post-operative morbidity after cardiac surgery are to be implemented, then pre-operative risk assessment is necessary. Thirdly, due to the heterogeneity of the outcome definition and variations in methodological detail direct comparisons

or undertaking a meta-analysis are not feasible. Despite this, our review, conducted with considerable methodological rigor (for example, not employing any date restrictions, undertaking double independent searching, data extraction and quality assessments), is valuable in describing and summarising the current evidence in this area to enable subsequent work to be undertaken to improve morbidity burden after cardiac surgery.

In conclusion, this review identified 22 pre-operative risk prediction tools for morbidity outcome after cardiac surgery. Those including minor morbidities, focusing on the elderly and including Growth Differentiation Factor 15 biomarker performed well. However, due to the methodological heterogeneity of studies, the lack of ability to undertake direct comparisons or a meta-analysis does limit the scope of conclusion that can be made as they all measure and predict different factors. Certainly, obtaining consensus, both nationally and internationally, would be beneficial for future work. Despite this current lack of standardisation, the review has highlighted that strategies to identify, predict and reduce morbidity after cardiac surgery should consider minor, as well as major morbidities, the impact of in-hospital complications on longer-term recovery and the increasing age, with accompanying multiple complex morbidities, of the current and future cardiac surgery population.

IMPLICATIONS FOR PRACTICE

- Clinical risk prediction models are important for person-centred care and can provide a basis for shared decision making
- Three models exhibit good discrimination and could be used in pre-operative clinics to optimise patient outcome and experience
- Age, frailty and multiple complex morbidities are important factors to consider
- New models that include minor morbidities and consider longer-term recovery are needed

ACKNOWLEDGEMENTS

None

FUNDING

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

DECLARATION OF CONFLICTING INTERESTS

The author(s) declare that there are no conflict of interest.

REFERENCES

1. Birkmeyer JD, Dimick JB, Birkmeyer NJO. Measuring the quality of surgical care: structure, process, or outcomes? *J Am Coll Surg* 2004; 198: 626–632.
2. Pearse RM, Clavien PA, Demartines N, et al. Global patient outcomes after elective surgery: Prospective cohort study in 27 low-, middle- and high-income countries. *Br J Anaesth* 2016; 117: 601–609.
3. Veluz J, Leary M. Chapter 126 - Cerebrovascular Complications of Cardiac Surgery. In: Caplan LR, Biller J, Leary MC, et al. (eds) *Primer on Cerebrovascular Diseases (Second Edition)*. Elsevier B.V., 2017, pp. 650–655.
4. Almashrafi A, Vanderbloemen L. Quantifying the effect of complications on patient flow, costs and surgical throughputs. *BMC Med Inform Decis Mak* 2016; 16: 136.
5. Lapar DJ, Crosby IK, Rich JB, et al. A contemporary cost analysis of postoperative morbidity after coronary artery bypass grafting with and without concomitant aortic valve replacement to improve patient quality and cost-effective care. *Ann Thorac Surg* 2013; 96: 1621–1627.
6. Rahmanian PB, Kröner A, Langebartels G, et al. Impact of major non-cardiac complications on

- outcome following cardiac surgery procedures: Logistic regression analysis in a very recent patient cohort. *Interact Cardiovasc Thorac Surg* 2013; 17: 319–327.
7. Efthymiou CA, O'Regan DJ. Postdischarge complications: what exactly happens when the patient goes home?. *Interact Cardiovasc Thorac Surg* 2011; 12: 130–134.
 8. Ngaage DL, Gooseman MR, Bulliment KL, et al. Is six weeks too long for the first outpatient review after cardiac surgery? FORCAST6. *Br J Cardiol*; 26. Epub ahead of print 2019. DOI: 10.5837/bjc.2019.008.
 9. Martin C, Holmes S, Martin L, et al. Abstract P331: The Impact of In-Hospital Postoperative Complications on Health Related Quality of Life in Cardiac Surgery Patients. In: *Circulation: Cardiovascular Quality and Outcomes*, https://www.ahajournals.org/doi/abs/10.1161/circoutcomes.4.suppl_1.ap331 (2018, accessed 5 April 2019).
 10. Myles PS, Viira D, Hunt JO. Quality of life at three years after cardiac surgery: relationship with preoperative status and quality of recovery. *Anaesth Intensive Care* 2006; 34: 176–83.
 11. Hansen TB, Zwisler AD, Berg SK, et al. Cardiac rehabilitation patients' perspectives on the recovery following heart valve surgery: A narrative analysis. *J Adv Nurs* 2016; 72: 1097–1108.
 12. Mehaffey JH, Hawkins RB, Byler M, et al. Cost of individual complications following coronary artery bypass grafting. *J Thorac Cardiovasc Surg* 2018; 155: 875-882.e1.
 13. Brown PP, Kugelmass AD, Cohen DJ, et al. The frequency and cost of complications associated with coronary artery bypass grafting surgery: results from the United States Medicare program. *AnnThoracSurg* 2008; 85: 1980–1986.
 14. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. *Lancet* 2008; 372: 139–144.
 15. Bruce J, Russell EM, Mollison J, et al. The measurement and monitoring of surgical adverse events. *Health Technol.Assess.* 2001; 5: 1–194.
 16. Goldfarb M, Drudi L, Almohammadi M, et al. Outcome reporting in cardiac surgery trials:

- Systematic review and critical appraisal. *J Am Heart Assoc* 2015; 4: 1–9.
17. Moza A, Benstoem C, Autschbach R, et al. A core outcome set for all types of cardiac surgery effectiveness trials: a study protocol for an international eDelphi survey to achieve consensus on what to measure and the subsequent selection of measurement instruments. Epub ahead of print 2015. DOI: 10.1186/s13063-015-1072-8.
 18. Moher D, Liberati A, Tetzlaff J, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med* 2009; 6: e1000097.
 19. Critical Appraisal Skills Programme. CASP Clinical Prediction Rule checklist, https://casp-uk.net/wp-content/uploads/2018/03/CASP-Clinical-Prediction-Rule-Checklist_2018_fillable_form.pdf (2018).
 20. Higgins J, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions*. 6.2 (updat. Cochrane, www.training.cochrane.org/handbook (2021).
 21. Hosmer D, Lemeshow S. Assessing the Fit of the Model. In: Shewhart W, Wilks S (eds) *Applied Logistic Regression*. New York: Wiley and Sons, 2000, pp. 160–164.
 22. Grinberg M, Jonke VM, Sampaio RO, et al. Validation of a new surgical risk score for heart valve surgery: VMCP. *Arq Bras Cardiol* 2009; 92: 301–306.
 23. Tan TC, Flynn AW, Chen-Tournoux A, et al. Risk prediction in aortic valve replacement: Incremental value of the preoperative echocardiogram. *J Am Heart Assoc* 2015; 4: 1–9.
 24. LaPar DJ, Likosky DS, Zhang M, et al. Development of a Risk Prediction Model and Clinical Risk Score for Isolated Tricuspid Valve Surgery. *Ann Thorac Surg* 2018; 106: 129–136.
 25. O'Brien SM, Feng L, He X, et al. The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: Part 2—Statistical Methods and Results. *Ann Thorac Surg* 2018; 105: 1419–1428.
 26. Afilalo J, Mottillo S, Eisenberg MJ, et al. Addition of frailty and disability to cardiac surgery risk scores identifies elderly patients at high risk of mortality or major morbidity. *Circ Cardiovasc Qual Outcomes* 2012; 5: 222–228.

27. Hsieh CH, Peng SK, Tsai TC, et al. Prediction for major adverse outcomes in cardiac surgery: Comparison of three prediction models. *J Formos Med Assoc* 2007; 106: 759–767.
28. Heringlake M, Charitos EI, Gatz N, et al. Growth differentiation factor 15: A novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients. *J Am Coll Cardiol* 2013; 61: 672–681.
29. Schoe A, Schippers EF, Ebmeyer S, et al. Predicting mortality and morbidity after elective cardiac surgery using vasoactive and inflammatory biomarkers with and without the EuroSCORE model. *Chest* 2014; 146: 1310–1318.
30. Wouters SC, Noyez L, Verheugt FW, et al. Preoperative prediction of early mortality and morbidity in coronary bypass surgery. *CardiovascSurg* 2002; 10: 500–505.
31. Magovern J, Sakert T, Magovern G, et al. A model that predicts morbidity and mortality after coronary artery bypass graft surgery. *J Am Coll Cardiol* 1996; 28: 1147–1153.
32. Staat P, Cucherat M, George M, et al. Severe morbidity after coronary artery surgery: development and validation of a simple predictive clinical score. *Eur.Heart J.* 1999; 20: 960–966.
33. Roques F, Gabrielle F, Michel P, et al. Quality of care in adult heart surgery: proposal for a self-assessment approach based on a French multicenter study. *Eur.J.Cardiothorac.Surg.* 1995; 9: 433–439.
34. Kurki TS, Kataja M. Preoperative prediction of postoperative morbidity in coronary artery bypass grafting. *AnnThoracSurg* 1996; 61: 1740–1745.
35. Fortescue EB, Kahn K, Bates DW. Development and validation of a clinical prediction rule for major adverse outcomes in coronary bypass grafting. *Am J Cardiol* 2001; 88: 1251–8.
36. Pitkanen O, Niskanen M, Rehnberg S, et al. Intra-institutional prediction of outcome after cardiac surgery: comparison between a locally derived model and the EuroSCORE. *EurJCardiothoracSurg* 2000; 18: 703–710.
37. Dupuis JY, Wang F, Nathan H, et al. The cardiac anesthesia risk evaluation score: a clinically

- useful predictor of mortality and morbidity after cardiac surgery. *Anesthesiology* 2001; 94: 194–204.
38. National Institute of Cardiovascular Outcomes Research (NICOR). *National Cardiac Audit Programme: National Adult Cardiac Surgery Audit (NACSA) 2021 summary report*. London, https://www.nicor.org.uk/wp-content/uploads/2021/10/NACSA-Domain-Report_2021_FINAL.pdf (2021).
 39. Parsonnet V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. *Circulation* 1989; 79: 13-12.
 40. Tuman KJ, McCarthy RJ, March RJ, et al. Morbidity and duration of ICU stay after cardiac surgery. A model for preoperative risk assessment. *Chest* 1992; 102: 36–44.
 41. Hattler BG, Madia C, Johnson C, et al. Risk stratification using the Society of Thoracic Surgeons Program. *AnnThoracSurg* 1994; 58: 1348–1352.
 42. The Society of Cardiothoracic Surgery in Great Britain and Ireland. *National Cardiac Surgery Activity and Outcomes Report 2002–2016*. The Society of Cardiothoracic Surgery in Great Britain and Ireland, <https://scts.org/resources/blue-book/> (2020).
 43. Kingston A, Robinson L, Booth H, et al. Projections of multi-morbidity in the older population in England to 2035: Estimates from the Population Ageing and Care Simulation (PACSim) model. *Age Ageing* 2018; 47: 374–380.
 44. Salisbury AC, Spertus JA. Realizing the Potential of Clinical Risk Prediction Models. *Circ Cardiovasc Qual Outcomes* 2015; 8: 332–334.
 45. Rahmanian PB, Adams DH, Castillo JG, et al. Predicting hospital mortality and analysis of long-term survival after major noncardiac complications in cardiac surgery patients. *Ann Thorac Surg* 2010; 90: 1221–1229.
 46. Hirose H, Inaba H, Noguchi C, et al. EuroSCORE predicts postoperative mortality, certain morbidities, and recovery time. *Interact Cardiovasc Thorac Surg* 2009; 9: 613–617.
 47. Toumpoulis IK, Anagnostopoulos CE, Swistel DG, et al. Does EuroSCORE predict length of stay

- and specific postoperative complications after cardiac surgery? *Eur J Cardio-thoracic Surg* 2005; 27: 128–133.
48. Andrade ING, de Moraes Neto FR, Andrade TG. Use of EuroSCORE as a predictor of morbidity after cardiac surgery. *Brazilian J Cardiovasc Surg* 2014; 29: 9–15.
 49. Wang TKM, Choi DHM, Haydock D, et al. Comparison of Risk Scores for Prediction of Complications following Aortic Valve Replacement. *Heart Lung Circ* 2015; 24: 595–601.
 50. Sanders J, Cooper J, Mythen MG, et al. Predictors of total morbidity burden on days 3, 5 and 8 after cardiac surgery. *Perioper Med* 2017; 6: 2.
 51. Riley R, Moons KG, Debray T, et al. Prognostic Model Research. In: Riley R, van der Windt D, Croft P, et al. (eds) *Prognostic Research in Healthcare*. Oxford: Oxford University Press, 2019, pp. 139–187.
 52. Riley R, Moons KG, Hayden J, et al. Prognostic Factor Research. In: Riley R, van der Windt D, Croft P, et al. (eds) *Prognosis Research in Healthcare*. Oxford: Oxford University Press, 2019, pp. 107–138.
 53. Alderwick H, Dixon J. The NHS long term plan. *BMJ* 2019; 364: 1–136.
 54. Lai FY, Abbasciano RG, Tabberer B, et al. Identifying research priorities in cardiac surgery: A report from the James Lind Alliance Priority Setting Partnership in adult heart surgery. *BMJ Open* 2020; 10: 1–9.
 55. Salenger R, Morton-Bailey V, Grant M, et al. Cardiac Enhanced Recovery After Surgery: A Guide to Team Building and Successful Implementation. *Semin Thorac Cardiovasc Surg*; 32. Epub ahead of print 2020. DOI: 10.1053/J.SEMTCVS.2020.02.029.
 56. Croke L. Optimizing patient health before surgery to improve outcomes. *AORN J* 2021; 114: P4–P6.
 57. D’Agostino RS, Jacobs JP, Badhwar V, et al. The Society of Thoracic Surgeons Adult Cardiac Surgery Database: 2019 Update on Outcomes and Quality. *Ann Thorac Surg* 2019; 107: 24–32.

58. Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. *JAMA* 1992; 267: 2344–2348.
59. Geraci JM, Rosen AK, Ash AS, et al. Predicting the occurrence of adverse events after coronary artery bypass surgery. *AnnInternMed* 1993; 118: 18–24.
60. Huijskes R V, Rosseel PM, Tijssen JG. Outcome prediction in coronary artery bypass grafting and valve surgery in the Netherlands: development of the Amphiascore and its comparison with the Euroscore. *EurJCardiothoracSurg* 2003; 24: 741–749.
61. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). *Eur.J.Cardiothorac.Surg.* 1999; 16: 9–13.

TABLES AND FIGURES

Table 1: The study characteristics of each included model (n=22): model name, year of publication, country, design, data collection period and population.

Study (author, reference and model name (where stated).	Year published	Country	Design (includes validation design where conducted)	Data collection period	Population (surgery type)
Parsonnet ³⁹	1989	USA	Retrospective	1982-1987	Open heart surgery
Higgins ⁵⁸ <i>Cleveland Clinic score</i>	1992	USA	Development: Retrospective Validation: Prospective	1986-1988	CABG
Tuman ⁴⁰	1992	Canada	Prospective	Not stated	Isolated cardiac surgery
Geraci ⁵⁹	1993	USA	Retrospective	1985-1986	CABG
Hattler ⁴¹	1994	USA	Prospective	1991-1993	CABG
Roques ³³ <i>Ontario Province Risk Score</i> <i>(French score)</i>	1995	France	Prospective	1993	Cardiac surgery
Kurki and Kataja ³⁴	1996	Finland	Retrospective	1990-1991	CABG

<i>CABDEAL score</i>					
Magovern ³¹	1996	USA	Retrospective	Development 1991-1992 Validation: 1993-1994	CABG
Staat ³²	1999	France	Retrospective	1996	CABG
Pitkanen ³⁶	2000	Finland	Development: Retrospective Validation: Prospective	Development 1992-1996 Validation: 1998-1999	Cardiac surgery
Dupuis ³⁷ <i>Cardiac Anaesthesia Risk Evaluation Score (CARE)</i>	2001	Canada	Prospective	Development: 1996-1998 Validation: 1998-1999	Cardiac surgery
Fortescue ³⁵ <i>Quality Measurement and Management Initiative (QMMI) score</i>	2001	USA	Prospective	1993-1995	CABG
Wouters ³⁰ <i>CORRAD score</i>	2002	Netherlands	Retrospective	Development: 1998 Validation: 1999-2000	CABG

Huijskes ⁶⁰ <i>Amphibia score</i>	2003	Netherlands	Retrospective	1997-2001	CABG +/- valve surgery
Hsieh ²⁷	2007	Taiwan	Retrospective	2004-2006	Cardiac surgery (>80 years old)
Grinberg ²² <i>Valve, Myocardial function, Coronary artery disease and Pulmonary artery pressure (VMCP) score</i>	2009	Brazil	Retrospective	Not stated	Heart valve surgery
Afilalo ²⁶	2012	USA and Canada	Prospective	2008-2010	CABG +/- valve replacement or repair (>70 years old)
Heringlake ²⁸	2013	Germany	Prospective	Development: 2009 Validation: 2008	Cardiac surgery
Schoe ²⁹	2014	Netherlands	Prospective	2006-2010	Elective cardiac surgery

Tan ²³	2015	USA and Canada	Retrospective	USA: 2008-2010 Canada: 2010-2012	Surgical AVR +/- CABG. Also included aortic surgery
LaPar ²⁴	2018	USA	Retrospective	2002-2014	Isolated tricuspid valve operations
O'Brien ²⁵ <i>STS Adult Cardiac Surgery Risk Model</i>	2018	USA and Canada	Retrospective	Development: 2011-2014 Validation: 2014-2016	Considered separately: CABG, Valve, and CABG and Valve

Table 2: The model characteristics of each included model (n=22): sample size, morbidity definition, timing of morbidity outcome, number of variables in the score and morbidity rate.

Study (author and reference)	Sample size (development and validation)	^aMorbidity definition for model development	Timing of morbidity outcome (eg in-hospital, 1 week)	^dNumber of variables in score (taken from text, where stated, otherwise counted from results table)	Morbidity rate (%)
Parsonnet ³⁹	Development: 3,500 Validation: 300	2	In-hospital ^b	15	23.5
Higgins ⁵⁸	Development: 5,051 Validation: 4,069	2	In-hospital	13	13.5
Tuman ⁴⁰	Development: 3,156 Validation: 394	2	In-hospital ^b	12	22.2 development 19.8 validation

Geraci ⁵⁹	Development: 2,213 (split in half for development and validation)	2	Post-operative	11	33
Hattler ⁴¹	Development: 728 No validation	2	Unclear – some done post-discharge	17	Not stated
Roques ³³	Development: 7,181 No validation	2	In-hospital ^b	8	Not stated
Kurki ³⁴	Development: 386 No validation	1	In-hospital	7	Not stated
Magovern ³¹	Development: 1,567 Validation: 1,235	3	In-hospital ^b	20	16 (major) 36 (minor)
Staat ³²	Development: 679 Validation: 226	3	Post-operative	6	23
Pitkanen ³⁶	Development: 4,592	4	Post-operative	14	22.0 development

	Validation: 821				18.4 validation
Dupuis ³⁷	Development: 2,000 Validation: 1,548	1 and 2	In-hospital	6 (statements)	20.7 development 22.2 validation
Fortescue ³⁵	Development: 6,237 Validation: 3,261	3	Post-operative	16	4.3
Wouters ³⁰	Development: 653 Validation: 969	4 and 3	Up to 6 months after surgery	20	19.1 development 21 validation
Huijskes ⁶⁰	7,282 (split 2/3 for development and 1/3 for validation)	4 and 3	In-hospital	8	17
Hsieh ²⁷	Development: 199 Validation: 423	4	In-hospital ^b	13	51.6
Grinberg ²²	Development: 768 No validation	1	In-hospital ^b	4 categories each with 4 categories/statements in each	Not stated

Afilalo ²⁶	Development: 152 No validation	2	In-hospital	Not stated specifically but combines 5 meter-gait speed, STS-PROMM and Nagi scales	24.3
Heringlake ²⁸	Pooled datasets due to some loss of samples, and low event rate (3.4% mortality): 1452	4	In-hospital ^b	16 ^c	14.4
Schoe ²⁹	Development: 679 No validation	4 and 3 and 1	In-hospital ^b	16 ^c	27.5
Tan ²³	Development: 432 No validation	2	In-hospital ^b	STS model (version or number of variables not stated) and echo parameters (3)	20.4
LaPar ²⁴	Development: 2,050	4	Post-operative	9	42%

	No validation				
O'Brien ²⁵	Development: 670,830 Validation: 579,335	2	In-hospital ^b	CABG: 50 Valve: 45 CABG and Valve: 47	All: 17.4 CABG: 15.0 Valve: 18.4 CABG and Valve: 28.3

^a Morbidity definition codes: 1: morbidity defined using surrogate marker (all were hospital LOS); 2. Specifically defined morbidity and mortality separately but included all outcomes in developing one model; 3. Included death in the morbidity definition; 4. Defined mortality and morbidity separately and constructed separate models for each. ^b In-hospital outcome only inferred but not explicitly stated. ^c EuroSCORE used was additive/model 1⁶¹ containing 15 variables; ^d The specific variables included for each model are available in Supplementary Table 1

Figure 1: Preferred Reporting Items for Systematic reviews and Meta-Analyses flow chart




Figure 2: Risk of bias summary




Figure 3: Risk of bias of individual studies

	Selection bias (population)	Selection bias (validation)	Performance bias	Detection bias	Reporting bias
Arliao et al 2012	+	+	+	+	?
Dupuis et al 2001	+	+	+	+	?
Fortescue et al 2001	+	+	+	+	+
Geraci 1993	+	+	+	+	+
Grinberg et al 2009	+	+	+	+	+
Hattler et al 1994	?	+	+	+	+
Heringlake et al 2013	+	+	+	+	+
Higgins et al 1992	+	+	?	?	+
Hsieh et al 2007	+	+	+	?	+
Huijkes et al 2003	+	+	?	?	+
Kurki and Kataja 1996	+	+	+	+	+
LaPar et al 2016	+	+	+	+	+
Magovern et al 1996	+	+	+	+	+
O'Brien et al 2018	+	+	+	+	+
Parsonnet et al 1989	+	+	?	?	+
Pitkanen et al 2000	+	+	+	+	+
Roques et al 1995	?	?	?	?	?
Schoe et al 2014	+	+	+	?	+
Staat et al 1998	+	+	+	+	+
Tan et al 2015	+	+	?	+	+
Tunman et al 1992	+	+	?	?	+
Wouters et al 2002	+	+	+	+	+

Figure 4: The discriminatory power of each model




FIGURE LEGENDS

Figure 1: Preferred Reporting Items for Systematic reviews and Meta-Analyses flow chart.

Abbreviations: NA - Not applicable; Pre-op – pre-operative.

Figure 2: A summary of the overall risk of bias across all 22 studies included in Tables 1 and 2. Red = high risk of bias; Yellow = unknown risk of bias; Green = low risk of bias.

Figure 3: The risk of bias of the 22 individual studies included in Tables 1 and 2. Red (-) = high risk of bias; Yellow (?) = unknown risk of bias; Green (+) = low risk of bias.

Figure 4: For the models listed in Tables 1 and 2 (excluding three that studies that did not report the area under the receiver operating characteristic curve (area under ROC) or C-statistic), the individual effect sizes (squares) and their confidence intervals (95%) are shown. The size of the square reflects the random effect weight assigned to each study. There is significant heterogeneity between the studies so the random effects estimate for the overall effect is 0.72 (0.69-0.75) (diamond).

Abbreviations: ROC - receiver operating characteristic curve